Santos-Franco J.A.,National Autonomous University of Mexico |
Santos-Franco J.A.,ABC Hospital |
Lee A.,Hospital A Ngeles Del Pedregal |
Lee A.,Instituto Nacional Of Ciencias Medicas Y Nutricio N |
And 4 more authors.
Vascular and Endovascular Surgery | Year: 2012
The type of venous drainage of a direct carotid-cavernous fistula is an important issue to consider for the endovascular therapeutic decision. In case of an inadequate posterior drainage associated with a good anterior drainage, the facial vein is a useful alternative. The exclusive embolization with ethylene vinyl alcohol (EVOH Onyx), arterial and/or venous via the internal carotid artery (ICA) occlusion has been used successfully, in a few cases until now. Nevertheless, the use of this method through anterior transvenous approach has not been previously described. Presented here is the case of a 13-year-old female patient with left posttraumatic carotid-cavernous fistula, with predominant anterior drainage, as well as carrier of traumatic occlusion of the contralateral ICA. The treatment was by means of a transvenous approach with transient occlusion of the left ICA. © 2012 The Author(s).
PubMed | ABC hospital
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016
874 Background: BC is the second most frequent cancer in women. Several prognostic factor have been identified in early clinical stages. Most important of these is axillary lymph nodes (ALN) status. Various treatment strategies have been attempted in high risk pts.To determine recurrence free time and overall survival in stage II, premenopausal BC pts with 4 or more positive ALN.Premenopausal pts, less than 50 years old, with histologically confirmed BC, stages IIA and IIB with 4 or more positive ALN. After breast surgery they received FAC (500-50-500 mg/m2) every 21 days for 4 cycles, then paclitaxel 175 mg/m2 every 21 days for 4 cycles, followed by radiotherapy and hormonal therapy according to hormonal receptors status. We determine age, clinic and pathologic stage, disease free and overall survival.From 09/98 to 04/03 13 pts were enrolled, mean age 41.1 yrs, range 32 -49. T1 five pts were enrolled, T2 8 pts; mean tumor size 2.5 cm, mean cut positive ALN 13.1 range 4 -35. Stage IIA 5 pts, IIB 8. All pts were menstruating at the time of chemotherapy; 6 stopped menstruating during chemotherapy and did not regain menses. Radical mastectomy 11 pts, conservative 2. RE+/RP+ 9/9 pts, negative RE/RP 2/2, unknown RE/RP 2/2. HER2-neu + 2 pts, negative 7, unknown 4; P53+ 5 pts, negative 3, unknown 5. Mean follow-up time 20.2 mos, range 3 -57. All pts completed chemotherapy and radiotherapy, 10 pts received hormonotherapy after chemo. We detected 2 recurrences, 1 local which was treated with radical mastectomy and 1 to lung and pleura which was treated with chemotherapy. 2 deaths were registered, 1 tumor related, and 1 because sudden death which was unrelated to tumor activity. No correlation was observed between chemo scheme and prognostic factors.In this study, FAC followed by paclitaxel appears to reduce the incidence of recurrence in high risk patients. We do not observe a relation between chemotherapy effect and prognostic factors. These findings need to be confirmed with a longer follow-up time and larger population; therefore this will continue to be an ongoing study. No significant financial relationships to disclose.